Citius Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CTXR research report →
Price Chart
About the company
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies.
- CEO
- Leonard L. Mazur
- IPO
- 2014
- Employees
- 23
- HQ
- Cranford, NJ, US
Get TickerSpark's AI analysis on CTXR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $13.96M
- P/E
- -0.24
- Fwd P/E
- 2.31
- PEG
- -0.00
- P/S
- 1.96
- P/B
- 0.20
- EV/EBITDA
- -0.07
- Div Yield
- 0.00%
- Gross Margin
- 19.97%
- Op Margin
- -863.92%
- Net Margin
- -651.27%
- ROE
- -67.15%
- ROIC
- -67.62%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-214,250-2.2%
- Op Income
- $-38,525,608
- Net Income
- $-37,433,911+4.4%
- EPS
- $-3.38+43.4%
- OCF Growth
- +5.8%
- FCF Growth
- +5.8%
- 52W High
- $1.54
- 52W Low
- $0.37
- 50D MA
- $0.52
- 200D MA
- $0.64
- Beta
- 1.04
- RSI (14)
- 49
- Avg Volume
- 275.44K
No earnings-call transcripts are available for CTXR yet.
- Free Float
- 98.2%
- Shares Outstanding
- 27.45M
- Float Shares
- 26.96M
of shares held by institutions
44 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Capital Management LLC | 264.67K | ▲ 67.31K |
| Geode Capital Management, LLC | 254.72K | ▲ 39.19K |
| Vanguard Group Inc | 199.26K | ▲ 32.87K |
| Vanguard Fiduciary Trust Co | 165.00K | ▲ 87.25K |
| Citadel Advisors LLC | 124.91K | ▲ 124.91K |
| Blackrock, Inc. | 69.85K | 0 |
| Northern Trust Corp | 62.74K | 0 |
| Stonex Group Inc. | 36.41K | ▲ 36.41K |
| Ubs Group AG | 36.29K | ▲ 9.95K |
| Berthel, Fisher & Company Financial Services, Inc. | 29.35K | ▲ 9.00K |
| Two Sigma Securities, LLC | 23.33K | ▲ 13.32K |
| State Street Corp | 23.27K | 0 |
Held by 6 ETFs
Biggest fund positions in CTXR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 8, 25 | Mazur Leonard L | other | 125,490 |
| Aug 8, 25 | Mazur Leonard L | other | 89,388 |
| Aug 8, 25 | Mazur Leonard L | sell | 125,490 |
| Aug 8, 25 | Mazur Leonard L | sell | 89,388 |
| Aug 8, 25 | HOLUBIAK MYRON Z | other | 31,373 |
| Aug 8, 25 | HOLUBIAK MYRON Z | other | 22,344 |
| Aug 8, 25 | HOLUBIAK MYRON Z | sell | 22,344 |
| Aug 8, 25 | HOLUBIAK MYRON Z | sell | 31,373 |
| Nov 7, 24 | Webb Carol | other | 125,000 |
| Nov 7, 24 | Smith Robert Joseph | other | 125,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CTXR coverage
Recent articles, reports, and earnings notes.
No research on CTXR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CTXR report →Citius Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
prnewswire.com · Nov 11
Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe
prnewswire.com · Nov 4
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
gurufocus.com · Oct 26
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
prnewswire.com · Oct 26
Citius Pharmaceuticals to Participate in October 2026 Investor Conferences
prnewswire.com · Oct 12
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Stock Now Rated “Hold” by Wall Street Brokerages
defenseworld.net · Oct 8
Citius Pharmaceuticals (NASDAQ:CTXR) versus Tarsus Pharmaceuticals (NASDAQ:TARS) Financial Analysis
defenseworld.net · Sep 21
Brokerages Set Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) PT at $5.00
defenseworld.net · Sep 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.